Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Diabetes Monitoring Start-Ups:Building a Better Mousetrap or a Whole New Paradigm?

This article was originally published in Start Up

Executive Summary

All facets of diabetes are a big focus of start-up and venture capital interest these days--insulin, blood-glucose testing, and new small-molecule drugs. Blood glucose monitoring is one of the few areas of in vitro diagnostics that attracts a significant amount of investor interest. Startups in this field pick one of two tacts: to try to change the testing paradigm with revolutionary technologies or to introduce incremental improvements, which could help attract big corporate partners.

You may also be interested in...



Where are They Now? Checking in on Three Glucose-Monitoring Start-Ups

Laying out a strategy is one thing; executing it is another. That's why, from time to time, START-UP revisits companies it has written about in the past to find out what went according to plan, and what didn't. As we revisit the field of glucose monitoring--a field with a high attrition rate, we'll see if we can draw out some lessons, both from the successes and from the failures, for those starting out today. (Introduction to three separate articles in the December 2007 issue: "Pelikan Technologies Swoops in on the Big Four"; "A Decade of Development for SMSI: Will It Yield Improved Accuracy in CGM?" and "GlucoLight Makes Non-invasive Glucose Monitoring Real.")

Business & Technology Briefs (03/2007)

Brief summaries of recent product and clinical developments in the device industry, including developments in Cardiac and Peripheral Devices, Miniature Robotic Devices, and Diabetes Management.

Advances in Diabetes Management

The goals being touted in the treatment of diabetes are lofty, with the development of a functional and affordable artificial pancreas topping the list of ambitious undertakings in the industry. The pursuit of such a device has been a Holy Grail quest for some time now, and over the years the feasibility of developing a man-made mechanism to take the place of a faulty body organ has been treated with a share of optimism and skepticism. However, based on recent FDA approvals for multiple manufacturers, it appears the industry is closer than it has ever been to making this goal a reality.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

LL1133148

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel